In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerationsEdward Gane, Gillmore Julian, Björn Pilebro et al.|Journal of Hepatology|2022Cited by 5